The price of a medicine is rarely a one-off question for someone managing a chronic illness. It returns with the next prescription and the next month’s purchase. Jan Aushadhi’s proposition is to offer a lower-priced route to medicines through a dedicated generic-drug retail network.
The programme began in 2008, before Modi became prime minister. Its subsequent expansion is the relevant achievement. The Department of Pharmaceuticals’ annual report records 17,990 Jan Aushadhi Kendras opened by 31 December 2025, compared with a much smaller network in the scheme’s early years. [1]
Reviving and extending an existing scheme
A government account from July 2015 described assistance for opening outlets and plans to extend their reach. It placed the emphasis on making generic medicines available through the Jan Aushadhi system rather than developing a new class of drugs. The programme’s growth required procurement, distribution, pharmacists and outlet operators as well as central policy support. [2]
By 28 February 2025, a parliamentary reply counted 15,057 outlets opened across the country. The later annual-report figure shows the network’s continued expansion. Both are administrative totals for outlets opened; neither should be presented as an independent inspection establishing that every shop is operating every day with every listed product in stock. [4] [1]
What a lower price does—and does not—establish
The government’s March 2025 account states that Jan Aushadhi medicines are generally priced 50–80% below comparable branded medicines. That describes the programme’s price comparison. It does not mean every patient’s total treatment cost falls by the same proportion: a prescription may include several products, and care also involves consultations, tests and travel. [3]
A meaningful comparison must match the medicine, strength and dosage form. An inexpensive item that differs from the prescribed formulation is not automatically a substitute. Decisions about treatment remain matters for qualified clinicians and pharmacists, not a programme-wide price slogan.
The other constraint is availability. A national catalogue is useful only if the patient can obtain the relevant medicine at the needed time. For continuing treatment, the reliability of repeat supply matters alongside the first purchase.
Measuring the network’s public value
The Modi governments deserve credit for the scale-up, while the scheme’s earlier origin remains part of the record. The state’s contribution is the organised purchasing and retail channel; the benefit is realised through medicines actually dispensed.
Outlet growth and lower listed prices establish two important elements of that channel. A fuller account of affordability would also examine stock availability, dispensing quality and patients’ actual spending over time. The test is modest but demanding: whether the next prescription can be filled with the right medicine, at a price the patient can sustain.